Pharmaceuticals

Egrifta (Tesamorelin Acetate) Market 2026–2030: Emerging Trends and Forecast Opportunities

March 5, 2026March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the egrifta (tesamorelin acetate) market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Egrifta (Tesamorelin Acetate) Market show for the 2026–2030 period?

The historical expansion was driven by an escalating prevalence of HIV-associated lipodystrophy, adverse effects stemming from prolonged antiretroviral therapy, the successful clinical validation of GHRH analogs, an enhanced understanding of the dangers associated with visceral fat, and the continuing demand for precise abdominal fat reduction.

The anticipated expansion during the projection period stems from several factors, including the advancement of individualized HIV care, the widening array of peptide therapeutic candidates, an increase in the diagnosis of metabolic complications, favorable reimbursement policies for specialized drugs, and a heightened emphasis on the long-term quality of life for HIV patients.

Significant developments anticipated during the forecast period involve the emergence of prolonged-release peptide treatments, individualized approaches to lipodystrophy management, the broadening of applications for metabolic conditions, patient-focused injectable medications, and the increased adoption of specialty biological drugs.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20043&type=smp

What Drivers Are Shaping The Development Of The Egrifta (Tesamorelin Acetate) Market?

The future expansion of the egrifta (tesamorelin acetate) market is significantly propelled by the rising incidence of human immunodeficiency virus (HIV) cases. Human immunodeficiency virus (HIV) cases describe instances where individuals contract HIV, leading to a progressive weakening of their immune system. This increase in HIV can be partly attributed to inadequate public awareness and education regarding preventative strategies, including condom utilization and consistent testing, especially within vulnerable groups. Egrifta works by stimulating growth hormone release, which aids in reducing excess visceral fat and enhancing body composition, thereby improving the overall health and quality of life for people living with HIV. As an illustration, in May 2024, the Minnesota Department of Health, a US-based state health agency, reported 324 new HIV diagnoses in 2023, representing a 24% increase compared to 2022. Consequently, the expanding occurrence of human immunodeficiency virus (HIV) cases is fostering the growth of the egrifta (tesamorelin acetate) market.

Which Segments Are Contributing To The Growth Of The Egrifta (Tesamorelin Acetate) Market?

The egrifta (tesamorelin acetate) market covered in this report is segmented –

1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

3) By End-Users: Hospitals, Specialized Clinics, Home Care

Which Trends Are Influencing The Performance And Direction Of The Egrifta (Tesamorelin Acetate) Market?

The main trend in the egrifta (tesamorelin acetate) market focuses on creating advanced synthetic peptide drugs to enhance the efficacy of treatments for HIV-related lipodystrophy. Synthetic peptide drugs are artificially designed compounds intended to deliver specific therapeutic effects by mimicking or improving the action of naturally occurring peptides. For instance, in December 2024, Theratechnologies Inc., a Canada-based biopharmaceutical company, disclosed that production of EGRIFTA SV has recommenced after its contract manufacturer’s facility voluntarily ceased operations due to observations from an FDA inspection. A newly manufactured batch has successfully completed quality control and is pending release upon US Food and Drug Administration (FDA) approval of a prior approval supplement, with two further batches currently in production. The company is actively managing inventory to address patient demand until mid-January 2025 and is collaborating with the FDA to prevent a potential shortage in 2025. EGRIFTA SV is distributed solely within the United States.

Who Are The Core Companies Influencing Trends In The Egrifta (Tesamorelin Acetate) Market?

Major companies operating in the egrifta (tesamorelin acetate) market are Theratechnologies Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/egrifta-tesamorelin-acetate-global-market-report

Which Regions Are Projected To Dominate The Egrifta (Tesamorelin Acetate) Market In The Coming Years?

North America was the largest region in the egrifta (tesamorelin acetate) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Egrifta (Tesamorelin Acetate) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20043&type=smp

Browse Through More Reports Similar to the Global Egrifta (Tesamorelin Acetate) Market 2026, By The Business Research Company

Ethyl Acetate Market Report 2026

https://www.thebusinessresearchcompany.com/report/ethyl-acetate-global-market-report

Ethylene Vinyl Acetate Market Report 2026

https://www.thebusinessresearchcompany.com/report/ethylene-vinyl-acetate-global-market-report

Ecoa Esource And Clinical Trials Market Report 2026

https://www.thebusinessresearchcompany.com/report/ecoa-esource-and-clinical-trials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795